Bristol-Myers Squibb Company (NYSE:BMY) ranks among the Best Low Volatility Investments in December 2025. Cantor Fitzgerald reaffirmed its Neutral rating and $45 price target on Bristol-Myers Squibb Company (NYSE:BMY) on November 24. Recent data, according to the firm, offers “tangible evidence that FXIa inhibition can blunt thrombosis while sparing hemostasis,” which bolsters trust in BMY’S milvexian SSP program.
Pixabay/Public Domain
The firm described the event as “a needed win” after “a string of class setbacks” and forecast that Bristol-Myers shares would rise as “sentiment around milvexian resets positively.” This comes after Bristol-Myers Squibb Company had chosen to withdraw its Phase III Librexia-ACS trial for milvexian, a decision reached after an independent analysis revealed the trial was unlikely to meet its primary endpoint.
That said, Cantor Fitzgerald indicated that the sustainability of any favorable sentiment reset will rely on the outcome of Cobenfy ADEPT-2 data projected by year-end 2025 as well as investor willingness to “underwrite those increased odds of success for the milvexian Afib trial.”
Bristol-Myers Squibb Company is a biopharmaceutical company that discovers, develops, and manufactures innovative medicines to treat serious diseases.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
This article is originally published at Insider Monkey.
